Rezolute, Inc. — filing summary
Filing and period caveat: The supplied filing is an AntriaBio, Inc. Form 10-K for the fiscal year ended June 30, 2013, filed September 11, 2013. It is not identified as a Rezolute, Inc. filing or a 2012 Q4 report. The filing explains that a January 31, 2013 reverse merger made AntriaBio Delaware the operating business and accounting acquirer.
Business context and reporting period
AntriaBio was a development-stage biotechnology company focused on sustained-release diabetes therapies. Its lead candidate, AB101, is a proposed once-weekly basal insulin in preclinical development; AB201 was an early-stage long-acting GLP-1 concept. The company acquired PR Pharmaceuticals’ assets for $500,000 in cash and contingent consideration, and discontinued the prior “Fits My Style” business. The reporting year followed a six-month transition period ended June 30, 2012; comparisons with that period and calendar 2011 are therefore not directly like-for-like.
Financial results and liquidity
| Metric | Year ended June 30, 2013 | Prior reported period |
|---|---|---|
| Revenue | $0 | $0; no revenue reported |
| Operating expenses | $6.107 million | $227,901 for six months ended June 30, 2012 |
| Operating loss | $6.107 million | $227,901 loss for six months ended June 30, 2012 |
| Net loss | $6.727 million ($0.18 per share) | $398,209 ($0.01 per share) for six months ended June 30, 2012 |
| Net cash used in operations | $1.628 million | $285,382 for six months ended June 30, 2012 |
- FY2013 compensation and benefits were $4.485 million, including $3.688 million of stock-based compensation. Interest expense was $568,859 and derivative expense was $157,761. Operating margins are not meaningful because there was no revenue.
- At June 30, 2013, cash was just $527; current assets were $815,549 and current liabilities were $5.266 million, implying a working-capital deficit of approximately $4.451 million. Total assets were $1.104 million, total liabilities $5.266 million, and stockholders’ deficit $4.162 million.
- Convertible notes totaled $3.733 million, carried interest rates of 8%–12%, and were classified as current. The filing says $2.908 million was payable on demand; the notes disclosure also reports $2.158 million matured by June 30, 2013, with another $750,000 maturing before the report date. No demand for payment had been received, and some matured notes remained unpaid.
- Financing activities provided $1.418 million, primarily from $1.575 million in convertible-note proceeds, less $157,500 of financing fees. Investing activities provided $185,114, including repayments on related-party notes receivable; the company also spent $500,000 on the PRP asset acquisition.
Material changes and unusual items
- The reverse merger changed the company’s business, ownership and reporting basis; Antria Delaware shareholders received 35.284 million shares, approximately 88.2% of the company after the transaction. The company reported 40 million shares outstanding at June 30, 2013.
- Operating expenses rose substantially from the reported prior periods, primarily reflecting compensation and stock-option expense following formation of the development-stage business and the merger. The comparison periods differ in length and business composition.
- The PRP asset purchase includes up to $44 million in milestone payments over five years: $2 million at Phase 2b initiation, $2 million upon specified licensing, $5 million at Phase 3 initiation, $10 million upon FDA or EMEA approval, and $25 million upon annual sales exceeding $500 million. No milestone had occurred by the report date.
- Related-party activity is material: $807,001 of related-party expenses were accrued as payable at year-end; $183,346 was due from related parties. A related-party note receivable and accrued interest totaled about $167,170 at year-end, and the note was past maturity.
Outlook, risks and controls
- Management said existing cash and expected operating cash flows would not sustain operations for more than one year. The company sought to raise as much as $30 million to fund development through an initial U.S. Phase 1 study, with plans at the time to raise approximately $15 million and potentially a further $15 million; it was initially targeting a $12 million financing. These were plans, not completed financings.
- Management planned animal studies and overseas Phase 1 and Phase 2 trials, with timelines contingent on funding, preclinical outcomes, clinical-material availability and regulatory approvals. It warned that unusable existing AB101 supply could delay studies by 12–18 months. Proposed later milestones included U.S. studies, Phase 3 trials and a 2018 NDA filing.
- The independent auditor’s financial-statement opinion was unqualified but included a going-concern paragraph. The filing states that recurring losses, a net capital deficiency and reliance on additional financing raise substantial doubt about the company’s ability to continue as a going concern.
- Key risks include clinical and regulatory failure, financing shortfalls and dilution, dependence on third-party manufacturers and research organizations, competition from established insulin products, intellectual-property challenges, and the possibility that AB101 will not gain market acceptance.
- Management found disclosure controls and internal control over financial reporting ineffective at June 30, 2013 due to a material weakness: duties were not segregated and controls did not prevent the controller from overriding the system. The company had no separate audit committee or financial expert and reported no director meeting Nasdaq’s independence standard.
Important facts for investors to verify
- Confirm the intended issuer and reporting period: the supplied document is AntriaBio’s FY2013 10-K, not a filing labeled Rezolute or 2012 Q4.
- Check subsequent financing, debt repayment or conversion, and whether holders exercised demand rights on the convertible notes.
- Verify current cash, related-party receivable collectability, and settlement of accrued related-party payables.
- Check whether AB101 supply, preclinical work and clinical milestones progressed as planned, and whether regulatory or trial results changed the development outlook.
- Review any later disclosure on the going-concern uncertainty, internal-control remediation, and the contingent PRP purchase obligations.